Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
Journal of Movement Disorders · 31.01.2025 · 18 (1) · 35-44
DOI: 10.14802/jmd.24127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Movement Disorders, erschienen am 31.01.2025. Verfasst von Jin Whan Cho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HLB Pharmaceutical Co., LTD..
Abstract (Originalsprache)
Objective
We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).
Methods
Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.
Results
A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).
Conclusion
Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Neurology, SMG-SNU Boramae Medical Center, Seoul, Korea.
- Department of Neurology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.
Förderung
- HLB Pharmaceutical Co., LTD.
Zitieren
APA
Cho, J. W., Lee, J. Y., Kim, H. J., Kim, J. S., Park, K. W., Choi, S. M., Lyoo, C. H., & Koh, S. B. (2025). Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration. Journal of Movement Disorders, 18(1), 35-44. https://doi.org/10.14802/jmd.24127
Vancouver
Cho JW, Lee JY, Kim HJ, Kim JS, Park KW, Choi SM, et al. Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration. Journal of Movement Disorders. 2025;18(1):35-44. doi:10.14802/jmd.24127
BibTeX
@article{Cho2025,
author = {Cho, Jin Whan and Lee, Jee-Young and Kim, Han-Joon and Kim, Joong-Seok and Park, Kun-Woo and Choi, Seong-Min and Lyoo, Chul Hyoung and Koh, Seong-Beom},
title = {Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration},
journal = {Journal of Movement Disorders},
year = {2025},
volume = {18},
number = {1},
pages = {35--44},
doi = {10.14802/jmd.24127}
}
EUVIMED